Ribomic Inc. Reports Improved Financial Results for Nine Months Ending December 2024
Ribomic Sees FY Loss Y1.40B
Ribomic 9-Mos Parent Loss Y740.00M Vs Loss Y802.00M
Ribomic: Summary of financial results for the 3rd quarter of the fiscal year ending March 31, 2025 [Japanese GAAP] (unconsolidated)
Volume change rate ranking (9 o'clock hour) - Data SEC, Nichicon, etc. are ranked.
In the volume change rate ranking, comparing the average volume over the last five days with the volume on the day of distribution allows insight into market participants' interests, such as trends in stock selection. ■ Top volume change rates [As of February 7, 9:32] (Compared to the average volume over the last five days) Stock Code Stock Name Volume Average Volume over 5 Days Volume Change Rate Stock Price Change Rate <3666> Technos JPN 2641000 107185.08 341.89% 0.015% <4591> Rebo
Soft market conditions, profit-taking sell-offs are prevailing [Emerging Markets individual stock Global Strategy].
[Emerging Markets Individual Stock Global Strategy] Today's emerging markets are expected to show a sluggish performance. In the US stock market yesterday, October 6th, the Dow Inc decreased by 125.65 points (-0.28%) to 44,747.63 dollars, reversing after three days. Expectations for additional interest rate cuts and strong earnings from some major companies supported stock prices, but rising caution ahead of employment statistics led to a decline in the Dow. On the other hand, the Nasdaq saw strong buying activity in high-tech stocks due to expectations surrounding Artificial Intelligence (AI), which expanded gains towards the end of the day. Today's emerging
Lear Gate, Ribomic and others.
<2385> The subsidiary NRL Pharma of General Medical Research Institute has obtained a patent. <4591> Announcement regarding the success of the low-dose group in the Phase II clinical trial of the drug for treating achondroplasia (umedaptanib pegol) at the Ribomic Fusion Conference 2025. <4592> The second manufacturing results related to the approval conditions for the shipping of Sun Bio Acugo for intracranial transplantation. <4891> Regarding TIM's TMS-007 (JX10).
Key points of the PTS on the 6th = Meiko, Nichias, SanBio ETC.
▽Tokyo Metro <9023.T> announced its financial results for the cumulative third quarter of the fiscal year ending March 2025 (April to December). Consolidated operating profit increased by 20.2% year-on-year to 77.75 billion yen. The activation of economic activities has led to an increase in passenger transportation revenue. ▽Mamiya OP <7991.T> announced an upward revision of its performance forecast for the fiscal year ending March 2025. Consolidated operating profit was increased from 4.4 billion yen to 6.4 billion yen (a 32.3% increase compared to the previous term). Demand for currency identification machines compatible with new banknotes has risen. The year-end Dividends that were previously undecided were mentioned.
Express News | [Change Report] SMBC Nikko Securities reported that their Shareholding in Recombibody (4591.JP) has decreased to 2.81%.
Express News | [Change Report] SMBC Nikko Securities reported a decrease in Shareholding of Ribomic (4591.JP) to 7.15%.
Stocks that moved the previous day part 2: Liberata, BTM, HPC Systems, ETC.
Stock Name <Code> Closing price on the 9th ⇒ Change from the previous day NISSAN MOTOR CO <7201> 446.5 -20.9 Moves continue with an awareness of the integration discount with Honda. ROHM <6963> 1495.5 -64 Citigroup Securities has lowered the Target Price. Kura Sushi <2695> 2770 -126 The financial results of the U.S. subsidiary were viewed positively. Mitsui High-Tec <6966> 867 -49 There are also profit-taking actions due to the rebound from the stock price rise since the beginning of the year. MAZDA MOTOR CRP <7261> 1048.5
The Tokyo Stock Exchange Growth Index has slightly declined, briefly rising into positive territory but then losing momentum.
Tokyo Stock Exchange Growth Market Index 825.08 -0.46 / Volume 0.1 billion 85.09 million shares / Trading value 134.6 billion yen. Tokyo Stock Exchange Growth Market 250 Index 643.42 -0.25 / Volume 0.1 billion 8.41 million shares / Trading value 101.2 billion yen. Today's growth market saw a slight downturn in both the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index, with 218 stocks rising, 349 stocks declining, and 37 unchanged. Today's growth market experienced a complicated interplay of buying and selling.
Stocks that moved or were traded in the first half of the session.
* Nexstage <3186> 1531 +115 Morgan Stanley MUFG Securities has raised the Target Price. * Tamura Manufacturing <6768> 543 +34 Expectations for expansion of Datacenter demand are being promoted. * Honeys HD <2792> 1721 +1069 - The November quarter is expected to turn to an increase in operating profit. * World <3612> 2611 +157 Upward revision of full-year performance and Dividends estimates. * Take and Give Needs <4331> 1015 +54 Dividends policy.
Ribomic and other ETC [stocks of interest viewed from volume change]
Stock closing prices compared to the previous day Volume *<4558>* Chukyo Pharmaceutical 229,235,302,700 *<4591>* Ribomic 106,233,886,9200 *<3604>* Kawamoto Industry 954,150,115,5400 *<2351>* ASJ 391,453,30500 *<7980>* Shigematsu Manufacturing 828,447,8300 *<3550>* Studio Atao 204,810,6900 *<5110>* Sumitomo Rubbers 1,769.5 20.56 697,600 *<3744>* Saios 39,629,218,500 *<
Eid, Enechange and others [Emerging Markets press release]
Acquired part of the Stocks of DFree, which is involved in the planning, development, and sales of the solution 'DFree' that alleviates the concerns and burdens of Yukaria excretion, and Mitsukari, which develops and operates the HRTech 'Mitsukari' that understands and analyzes the personality and compatibility of each individual to maximize the power of individuals and organizations. Recognized a subsidy benefit of 0.04 billion yen from Enechange as non-operating income. Significant exercise of subscription rights for the 17th subscription rights of Ribomik (with exercise price revision provisions) occurred on the 6th.
The Tokyo Stock Exchange Growth Index continues to rise, with a focus shifting toward interim purchases.
Tokyo Stock Exchange Growth Market Index 825.54 +3.18 / Volume 0.2 billion 1.01 million shares / Trading value 127.6 billion yen. Tokyo Stock Exchange Growth Market 250 Index 643.67 +2.73 / Volume 96.57 million shares / Trading value 94.9 billion yen. Today, the growth market showed a continuation of gains, with the Tokyo Stock Exchange Growth Market Index and the Tokyo Stock Exchange Growth Market 250 Index both rising. The number of rising stocks was 261, declining stocks numbered 306, and there were 38 unchanged stocks. Today's growth market was strong. The previous day's (7th) USA market was soft.
Emerging Markets stock digest: BTM rebounded for the first time in six days and reached a daily maximum limit, while Ribomic significantly rebounded.
<303A> visumo 2340 -700 stop-limit. After updating the all-time high in the morning, it has shifted to a selling dominance due to a pause in buying. Visumo went public on December 26 last year, debuting at 1,036 yen, which is 34.5% above the offering price (770 yen). Since then, it has continued to hit the daily upper limit, and on the morning of the 8th, it surged to 3,110 yen, nearly three times the debut price. The operating profit Financial Estimates for the fiscal year ending March 2025 is expected to be 0.073 billion yen, which is a 291.8% increase compared to the previous term.
Individual stock information.
Justplan <4287.T> continued to rise for six days, remaining unchanged amid significant gains. A stock buyback limit of 600,000 shares (4.93% of issued shares excluding treasury stock) and a 200 million yen buyback program were established. The acquisition period is from January 8 to July 31. Additionally, 283,700 treasury shares currently held (2.23% of issued shares before retirement) will be retired effective January 15. McDonald's <2702.T> declined continuously. The preliminary monthly revenue for December was announced, showing same-store sales decreased by 0.4% compared to the same month last year, marking the fifth consecutive month of decline.
Ribomic soared sharply, reaching a temporary stop high, with a patent application resulting from joint research with Mitsubishi Corporation Life Sciences.
Ribomic <4591.T> surged, reaching a stop-high of 113 yen at one point, rising by 30 yen. After the close on the 7th, it was announced that the company succeeded in the creation and development of an 'anti-neutrophil elastase aptamer,' which serves as a candidate for Cosmetic raw materials, in joint research with Mitsubishi Corporation Life Sciences <8058.T>. The results were considered significant as the patent application was filed jointly with Mitsubishi Corporation Life Sciences at the patent office. Mitsubishi Corporation Life Sciences deals with food ingredients, health materials, Cosmetic raw materials, etc.
Stocks reaching the upper and lower limits in the first half of the trading session.
■Limit Up <269A> Sapeet <278A> Terra Drone <3604> Kawamoto Sangyo <4591> Ribomic <5247> BTM <6864> NF Holdings ■Limit Down <303A> visumo * Includes temporary limit ups and downs (listed prices).